What is the address of Dokter Elke Van Mieghem, Oncologie?

The registered office of Dokter Elke Van Mieghem, Oncologie is located at Hulzenstraat 140, 3570 Alken.

Is Dokter Elke Van Mieghem, Oncologie still active?

Yes. According to the CBE (16 September 2026) Dokter Elke Van Mieghem, Oncologie is active, legal situation “Normale toestand”, started on 6 February 2017.

Is Dokter Elke Van Mieghem, Oncologie registered on Peppol?

Yes, Dokter Elke Van Mieghem, Oncologie is registered on the Peppol network with ID 0208:0670785088.

What is the enterprise number of Dokter Elke Van Mieghem, Oncologie?

The enterprise number of Dokter Elke Van Mieghem, Oncologie is BE0670785088.

When was Dokter Elke Van Mieghem, Oncologie founded?

Dokter Elke Van Mieghem, Oncologie was founded on 6 February 2017.

Who are the directors of Dokter Elke Van Mieghem, Oncologie?

According to the 2025 annual accounts, the directors of Dokter Elke Van Mieghem, Oncologie are: Elke Van Mieghem.

Is Dokter Elke Van Mieghem, Oncologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 February 2017; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dokter Elke Van Mieghem, Oncologie make in 2025?

Dokter Elke Van Mieghem, Oncologie posted a profit after taxes of € 84,866 in financial year 2025.

What is the revenue of Dokter Elke Van Mieghem, Oncologie?

As a small company, Dokter Elke Van Mieghem, Oncologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 166,760.

Dokter Elke Van Mieghem, Oncologie (Private Limited)

Q: What does Dokter Elke Van Mieghem, Oncologie do?

Dokter Elke Van Mieghem, Oncologie is filed with the CBE under the catch-all “Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten”. Also registered: specialist medical practice. Private Limited, started on 6 February 2017, 1 establishment.

Dossier Dokter Elke Van Mieghem, Oncologie, printed on 16 September 2026 from databakkes.be/en/0670785088/dokter-elke-van-mieghem-oncologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dokter Elke Van Mieghem, Oncologie from Alken, company number BE0670785088, closed financial year 2025 with a result of € 84,866 after tax. For that financial year Dokter Elke Van Mieghem, Oncologie recorded a gross margin of € 166,760 and equity of € 162,178. Compared with financial year 2024, the result moved from € 86,976 to € 84,866. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 30, 2026.

What it is worth Healthy

€ 162,178

▼ 19% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 84,866

▼ 2% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 44,644

▼ 18% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 123,529 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 11,628

▲ 99% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 715

▼ 52% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 113,111 Gross margin 2022: € 113,111 First fiscal year in the series	€ 157,658 Gross margin 2023: € 157,658 ▲ 39% vs 2022 (€ 113,111) Favourable step	€ 171,206 Gross margin 2024: € 171,206 ▲ 9% vs 2023 (€ 157,658) Favourable step	€ 166,760 Gross margin 2025: € 166,760 ▼ 3% vs 2024 (€ 171,206) Unfavourable step	▼ 3%
Profit after taxes	€ 33,301 Profit after taxes 2022: € 33,301 First fiscal year in the series	€ 76,740 Profit after taxes 2023: € 76,740 ▲ 130% vs 2022 (€ 33,301) Favourable step	€ 86,976 Profit after taxes 2024: € 86,976 ▲ 13% vs 2023 (€ 76,740) Favourable step	€ 84,866 Profit after taxes 2025: € 84,866 ▼ 2% vs 2024 (€ 86,976) Unfavourable step	▼ 2%
Equity	€ 107,714 Equity 2022: € 107,714 First fiscal year in the series	€ 149,160 Equity 2023: € 149,160 ▲ 38% vs 2022 (€ 107,714) Favourable step	€ 200,842 Equity 2024: € 200,842 ▲ 35% vs 2023 (€ 149,160) Favourable step	€ 162,178 Equity 2025: € 162,178 ▼ 19% vs 2024 (€ 200,842) Unfavourable step	▼ 19%
Total debts	€ 217,629 Total debts 2022: € 217,629 First fiscal year in the series	€ 131,342 Total debts 2023: € 131,342 ▼ 40% vs 2022 (€ 217,629) Favourable step	€ 46,814 Total debts 2024: € 46,814 ▼ 64% vs 2023 (€ 131,342) Favourable step	€ 36,321 Total debts 2025: € 36,321 ▼ 22% vs 2024 (€ 46,814) Favourable step	▼ 22%
Cash	€ 29,548 Cash 2022: € 29,548 First fiscal year in the series	€ 35,641 Cash 2023: € 35,641 ▲ 21% vs 2022 (€ 29,548) Favourable step	€ 54,403 Cash 2024: € 54,403 ▲ 53% vs 2023 (€ 35,641) Favourable step	€ 44,644 Cash 2025: € 44,644 ▼ 18% vs 2024 (€ 54,403) Unfavourable step	▼ 18%
Retained profit	€ 89,114 Retained profit 2022: € 89,114 First fiscal year in the series	€ 130,560 Retained profit 2023: € 130,560 ▲ 47% vs 2022 (€ 89,114) Favourable step	€ 182,242 Retained profit 2024: € 182,242 ▲ 40% vs 2023 (€ 130,560) Favourable step	€ 143,578 Retained profit 2025: € 143,578 ▼ 21% vs 2024 (€ 182,242) Unfavourable step	▼ 21%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 35,294 Dividend 2023: € 35,294 Unchanged (€ 0) Unchanged	€ 35,294 Dividend 2024: € 35,294 Unchanged (€ 35,294) Unchanged	€ 123,529 Dividend 2025: € 123,529 ▲ 250% vs 2024 (€ 35,294) Unchanged	▲ 250%
Bank debt	€ 131,019 Bank debt 2022: € 131,019 First fiscal year in the series	€ 85,282 Bank debt 2023: € 85,282 ▼ 35% vs 2022 (€ 131,019) Favourable step	€ 38,998 Bank debt 2024: € 38,998 ▼ 54% vs 2023 (€ 85,282) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 38,998) Favourable step	▼ 100%
Balance sheet total	€ 325,343 Balance sheet total 2022: € 325,343 First fiscal year in the series	€ 280,502 Balance sheet total 2023: € 280,502 ▼ 14% vs 2022 (€ 325,343) Unchanged	€ 247,656 Balance sheet total 2024: € 247,656 ▼ 12% vs 2023 (€ 280,502) Unchanged	€ 198,499 Balance sheet total 2025: € 198,499 ▼ 20% vs 2024 (€ 247,656) Unchanged	▼ 20%

Key figures of Dokter Elke Van Mieghem, Oncologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dokter Elke Van Mieghem, Oncologie?

What happened at Dokter Elke Van Mieghem, Oncologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 30, 2026 New annual accounts for financial year 2025: profit of € 84,866 (▼ 2% vs 2024). filed late Source: NBB ↗
Feb 6, 2017 New establishment in Alken. KBO
2017 Elke Van Mieghem became a director. NBB
Feb 6, 2017 Start of the company according to the CBE. KBO

In short

From € 33,301 profit in 2022 to € 84,866 profit in 2025.

Paid € 87,911 in corporate taxes since 2022.

Best year ever: 2024, with € 86,976 profit.

Paid out € 194,118 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dokter Elke Van Mieghem, Oncologie? We notify you, reason included.

Follow Dokter Elke Van Mieghem, Oncologie

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Elke Van Mieghem

Dokter Elke Van Mieghem, Oncologie

Inwendige ziekten Sint-Trudo

Behind Dokter Elke Van Mieghem, Oncologie is Elke Van Mieghem. It owns Inwendige ziekten Sint-Trudo itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Elke Van Mieghem

Director

Also active at: Inwendige Ziekten Sint-Trudo

since 2017

Establishments

Establishment units

Physical locations of this company

Registered office

Hulzenstraat 140

3570 Alken

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

DOKTER KOEN PALMERS

€ 57,854 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0670.785.088

VAT number

BE 0670.785.088

Registered office

Hulzenstraat 140, 3570 Alken

Names & denominations

Dokter Elke Van Mieghem, Oncologie

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

6 February 2017

Peppol

Active · Active since 9 Jan 2026

Activities · NACE

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Overige gespecialiseerde wetenschappelijke en technische activiteiten

Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗

Dokter Elke Van Mieghem, Oncologie

Financials

What happened to Dokter Elke Van Mieghem, Oncologie?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions